Table 4.
Characteristic1 | n | (%) | Overall Survival from EOI | Overall Survival from EOC | |||||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | ||||
Age at diagnosis | <10 years | 39 | (49) | 1 | -- | 0.917 | 1 | -- | 0.893 |
≥10 years | 41 | (51) | 1.1 | 0.19, 6.25 | 1.13 | 0.19, 6.55 | |||
Initial WBC (/uL) | <50,000 | 57 | (71) | 1 | -- | 0.372 | 1 | -- | 0.396 |
≥50,000 | 23 | (29) | 0.44 | 0.07, 2.69 | 0.45 | 0.07, 2.91 | |||
Cytogenetic classification2 | Neutral | 59 | (74) | 1 | -- | 0.163 | 1 | -- | 0.165 |
Favorable | 15 | (19) | 0.54 | 0.05, 5.37 | 0.53 | 0.05, 5.38 | |||
Adverse | 6 | (7) | 7.61 | 1.02, 56.64 | 7.68 | 1.01, 58.16 | |||
Induction therapy3 | COG SR | 26 | (32) | 1 | -- | 0.561 | 1 | -- | 0.567 |
COG HR | 54 | (68) | 2.05 | 0.18, 22.75 | 2.05 | 0.18, 23.47 | |||
HSCT in CR14 | No | 69 | (89) | 1 | -- | 0.674 | 1 | -- | 0.712 |
Yes | 11 | (14) | 1.44 | 0.26, 7.87 | 1.4 | 0.24, 8.15 | |||
EOI MRD5 | Negative | 57 | (71) | 1 | -- | 0.003 | -- | -- | -- |
Positive | 23 | (29) | 9.57 | 1.94, 47.20 | -- | -- | |||
EOI/EOC MRD5 | neg/neg | 57 | (71) | -- | -- | -- | 1 | -- | 0.028 |
pos/neg | 13 | (16) | -- | -- | -- | 9.32 | 1.45, 59.85 | ||
pos/pos | 3 | (4) | -- | -- | -- | 10.03 | 0.64, 157.42 | ||
pos/unk. | 7 | (9) | -- | -- | -- | 9.94 | 1.51, 65.47 |
All candidate predictors in Table 1 tested in stepwise multivariable model with endpoint of OS, see methods. Age, WBC, cytogenetics included as a priori “base” model irrespective of significance.
As per AALL08B1 criteria; excludes two patients with unknown cytogenetics.
COG SR/HR = Children’s Oncology Group three drug (steroid, vincristine, asparaginase) or four drug induction (+daunorubicin) for NCI/Rome Standard Risk or High Risk ALL
Hematopoetic stem cell transplantation (HSCT) in first remission (CR1).
MRD considered positive ≥0.01% at either time-point. EOI = end of induction, EOC = end of consolidation WBC = white blood cell count.